Safety and efficacy of external application of Non-Steroidal Anti-Inflammatory Drugs(NSAIDs) with renal function in patients of type 2 diabetic nephropathy

Safety and efficacy of external application of Non-Steroidal Anti-Inflammatory Drugs(NSAIDs) with renal function in patients of type 2 diabetic nephropathy - Effect of NSAIDs external application in type 2 diabetic nephropathy patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009520

Enrollment

Registered

2012-12-11

Start date

2010-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

There was no placebo group. Only one group used loxoprofen.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of diabetic nephropathy(from stage II to IV) Patients with Lunbago or knee pain.

Exclusion criteria

Exclusion criteria: Patients who take NSAIDs. Patients for less than one month after an operation. Patients who severe liver dysfunction and severe heart failure. The patient who has hypersensitivity to loxoprofen. The patient of aspirin-induced asthma.

Design outcomes

Primary

Measure	Time frame
Concentration of urinary Prostaglandin E2, serum loxoprofen(trans-OH body), estimated GFR(ml/min/m2),serum cystatin C,blood pressure and VAS(visual analogue scale). Before and five days after consecutive external application,respectively	—

Countries

Japan

Contacts

Public ContactHisazumi Araki

Shiga University of Medical Science Internal medicine

haraki@belle.shiga-med.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026